The results showed that low expression of FOXO3A was significantly associated with aggressive pathological stage (P = 0.026), lymphovascular invasion (P < 0.001), lymph node metastasis (P = 0.040), and adjuvant therapy (P = 0.048). The gene discussed is FOXO3; the disease is metastatic malignant neoplasm in the lymph nodes.